Acino Holding AG : Delisting of Acino Holding AG after cancellation of all publicly held registered shares

NEWS RELEASE - PRESSEMITTEILUNG

Delisting of Acino Holding AG after cancellation of all publicly held registered shares Aesch, January 7, 2014, 07.00 hrs - On December 20, 2013, SIX Swiss Exchange (SIX) approved Acino Holding AG's request for the delisting of its registered shares. The delisting will take place once the decision of the Kantonsgericht (cantonal court) Basel- Landschaft in Liestal on the cancellation of all remaining publicly held registered shares will have come into legal force. The delisting is conditional upon the adherence of Acino

Holding AG to certain disclosure requirements. In particular, Acino Holding AG is obliged to publish the date of the delisting at least five trading days in advance.
On December 23, 2013, SIX also exempted Acino Holding AG from certain disclosure obligations as outlined in the listing rules of SIX. These exemptions include the obligation to publish an Annual Report for the year 2013 including information on the company's Corporate Governance, the obligation to publish ad hoc releases (ad hoc publicity), the obligation to disclose management transactions, the obligation to maintain a corporate calendar, and the obligation to disclose certain important business events.
The exemption was granted until the Best Price Rule expires (in accordance with Article 10 of the Ordinance of the Takeover Board on public takeover offers of August 21, 2009) in
the context of the public tender offer of Pharma Strategy Partners GmbH, Aesch BL, for all publicly held registered shares of Acino Holding AG, i.e. presumably until June 5, 2014.

About Acino

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 788 employees and generated revenues of EUR 143 million in the first half-year 2013.

On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the

Acino shares from the stock exchange.

Contact

Robert Schmid

Media & Investor Relations Phone [phone] [e-mail]

Acino Holding AG Dornacherstrasse 114

CH-4147 Aesch

Phone [phone]

Fax [phone] www.acino-pharma.com